AbbVie Inc (N:ABBV)

Business Focus: Pharmaceuticals

Apr 23, 2024 08:00 am ET

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands

Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics Loyalty Rewards ProgramIRVINE, Calif., April 23, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesth

Apr 18, 2024 08:31 am ET

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid taper regimen1− The safety profile in GCA was generally consistent with that in approved indications, and no new safety signals were identified1 − The clinical program reflects AbbVie's history of developing new treatment options for patients with immune-me

Apr 12, 2024 04:00 pm ET

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE:

Apr 12, 2024 01:53 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) investors concerning the Company’s possible violations of federal securities laws.

Apr 12, 2024 07:30 am ET

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine- Seventy percent of subjects achieved ≥50% reduction in monthly migraine days at Weeks 13-16 and this was consistent during the 48 weeks of open-label treatment- Findings will be showcased in an oral presentation at the American Academy of Neurology (AAN) Annual Meeting Scientific Platform Session for Emerging Science

Apr 10, 2024 02:45 pm ET

The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE:

Apr 09, 2024 08:00 am ET

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne

From the makers of BOTOX® Cosmetic, two new SkinMedica® acne products help address skin blemishes and can be combined with in-office DiamondGlow®IRVINE, Calif., April 9, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the launch of two new products from SkinMedica® by the makers of BOTOX® Cosmetic. The SkinMedica® Acne Clarifying Treatment and SkinMedica® Pore Purifying Gel Cleanser are breakthroughs in skincare, providing effective and balanced care for people with acne-prone skin. The two products, along with the SkinMedica® Pore Purifying Pro-Infu

Apr 04, 2024 08:00 am ET

AbbVie to Host First-Quarter 2024 Earnings Conference Call

NORTH CHICAGO, Ill., April. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

Apr 03, 2024 08:30 am ET

Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®

Offering $200 Off the First CoolSculpting® TreatmentIRVINE, Calif., April 3, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is announcing its second annual CoolMonth celebration featuring CoolSculpting® Elite. From April 1 through April 30, 2024, consumers can access CoolSavings promotions to help accelerate their body contouring journey. Leveraging last year's success, which saw more than 62,000 treatments during the month-long celebration1, the brand aims to encourage and inspire more consumers on their body contouring journey to discuss options with their trained

Apr 01, 2024 11:51 am ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq –

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...

Apr 01, 2024 07:50 am ET

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year...

Mar 25, 2024 11:09 am ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN

Mar 25, 2024 11:00 am ET

Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics

Allergan Aesthetics is raising the conversation on patient safety and ethical standardsAs part of its established Aesthetics-Ethics program, this year's Anti-Age Medicine World Congress (AMWC) launches Moving the Needle on Ethics Book Thought-provoking articles and interviews with leading medical practitioners from around the world discuss the impact of ethical practices and aim to raise awareness and create discussion across the industryIRVINE, Calif., March 25, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) Company, announces Moving the Needle on Ethics- its collaboration

Mar 25, 2024 08:31 am ET

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC)NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-lik

Mar 25, 2024 08:30 am ET

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel,...

Mar 22, 2024 03:02 pm ET

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

- The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer (PROC) - Data show that ELAHERE treatment resulted in an overall survival benefit and reduced the risk of cancer progression by 35% - ELAHERE represents AbbVie's first approved solid tumor treatment following the recent acquisition of ImmunoGen

Mar 21, 2024 08:00 am ET

ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024

-- Two expert-led Allergan Medical Institute (AMI) symposia will explore a personalized approach to aesthetics, featuring live injection sessions with Dr Mauricio De Maio, Dr Mansi Mukherjee and Dr Steven Liew --

Mar 05, 2024 08:30 am ET

Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for the drugs used...

Mar 05, 2024 06:00 am ET

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials.

Feb 27, 2024 08:00 am ET

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea

Healis Therapeutics, a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), has released topline results from Phase III on Healis’ lead compound, CKDB-501A. The study results...

Feb 27, 2024 07:00 am ET

AbbVie to Present at the TD Cowen 44th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 8:10 a.m. Central time.

Feb 27, 2024 06:45 am ET

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)

- A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in patients with relapsed or refractory (R/R) follicular lymphoma (FL), demonstrating strong and durable treatment responses

Feb 22, 2024 07:05 am ET

AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunologyAbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by TentarixNORTH CHICAGO, Ill. and SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immu

Feb 21, 2024 07:00 am ET

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY

Feb 20, 2024 08:00 am ET

AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer

Richard A. Gonzalez to retire as AbbVie CEO to become Executive ChairmanTransition will occur on July 1, 2024NORTH CHICAGO, Ill., Feb. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr. Gonzalez, who has served as CEO since the company's formation in 2013, will retire from the role of CEO and become executive chairman of the board of directors, effective July 1, 2024. Additi

Feb 19, 2024 07:30 am ET

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)

– A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie's commitment to produce a portfolio of products that aim to improve the lives of patients living with inflammatory bowel diseases (IBD)– Oral data presentations include a new post-hoc analysis of clinical and endoscopic outcomes from the SEQUENCE trial comparing risankizumab (SKYRIZI®) versus ustekinumab, results from the COMMAND Phase 3 study of risankizumab as a maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC), and long-term safety result

Feb 15, 2024 11:03 am ET

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Feb. 15, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.

Feb 15, 2024 08:45 am ET

Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a substantial rate through the next decade. Fibromyalgia is a chronic condition whose symptoms severely impair...

Feb 12, 2024 06:37 am ET

AbbVie Completes Acquisition of ImmunoGen

Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolioImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignanciesImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populationsAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $11.05-$

Feb 08, 2024 07:00 am ET

AbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

VYALEV is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease (aPD) in Canada.Advanced Parkinson's disease patients now have a non-surgical treatment option that addresses an unmet need within this community.In clinical trials, patients taking VYALEV achieved the primary endpoint of a reduction in motor fluctuations and morning akinesia, as well as improvements in sleep quality and quality of life.1,2Announcement underscores AbbVie's longstanding commitment to deliver innovative medicines for people living with neurolog

Feb 06, 2024 11:00 am ET

Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVieAbbVie also has the option to explore the applicability of Calibr-Skaggs' sCAR-T platform in autoimmune diseasesCalibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches LA JOLLA, Calif., Feb. 6, 2024 /PRNewswire/ -- The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that

Feb 02, 2024 06:36 am ET

AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results

Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to 2023 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $54.318 Billion, a Decrease of 6.4 Percent on a Reported Basis and 5.9 Percent on an Operational BasisFull-Year Global Net Revenues from the Immunology Portfolio Were $26.136 Billion, a Decrease of 9.6 Percent on a Reported Basis, or 9.2 Percent on an Operational Basis, Due to Humira Biosimilar Co

Jan 31, 2024 10:00 am ET

Allergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-Expression

-- New report incorporates in-depth interviews, industry research and social listening to understand the role of individuality in the world of aesthetics --

Jan 29, 2024 09:59 am ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - E

Jan 26, 2024 05:41 pm ET

CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE

NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Cerevel Therapeutics (NasdaqCM: CERE) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Cerevel will receive $45.00 in cash for each share of Cerevel that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Jan 25, 2024 02:00 am ET

Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024

-- Expert-led symposium will explore key emerging themes in aesthetics, supported by injection session live from Allergan Aesthetics Center of Excellence in Italy --

Jan 23, 2024 07:00 am ET

Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.

ALLĒ SOLIDIFIES ITS POSITIONING WITH SATISFACTION SCORES IN THE NINETY-SECOND PERCENTILE BASED ON CONSUMER SURVEY

Jan 09, 2024 01:00 am ET

AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

- PRODUODOPA® (foslevodopa/foscarbidopa) is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of advanced Parkinson's disease

Jan 08, 2024 07:05 am ET

Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3

Phase 2 data in adults with hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg weekly or 300 mg every other week showed higher response rates in HiSCR 50 at week 16 than those treated with placebo1,2Higher response rates were also observed in patients receiving lutikizumab 300 mg weekly or 300 mg every other week than those treated with placebo in the secondary endpoint of skin pain NRS30 at week 16 among patients with baseline NRS≥31,2HS is a chronic, often debilitating inflammatory skin disease that can form lumps, abscesses a

Jan 04, 2024 11:22 am ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc.

Jan 04, 2024 07:45 am ET

AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies

Collaboration to leverage Umoja's VivoVecTM gene delivery platform and AbbVie's expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidatesNORTH CHICAGO, Ill. and SEATTLE, Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVecTM platform. The first agreement provides AbbVie an exclusive option to licens

Jan 04, 2024 07:00 am ET

AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call

NORTH CHICAGO, Ill., Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2023 financial results on Friday, February 2, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

Jan 02, 2024 07:00 am ET

AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Jan. 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D. senior vice president, development and regulatory affairs and chief medical officer, will present at 10:15 a.m. Central time.

Dec 26, 2023 02:27 pm ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc.

Dec 11, 2023 01:28 pm ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE)

Dec 11, 2023 08:31 am ET

Thinking about trading options or stock in Taiwan Semiconductor, AbbVie, Shell PLC, HashiCorp, or ON Semiconductor?

NEW YORK, Dec. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSM, ABBV, SHEL, HCP, and ON.

Dec 09, 2023 11:00 am ET

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congress- Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma

Dec 08, 2023 08:31 am ET

Thinking about trading options or stock in Taiwan Semiconductor, AbbVie, Shell PLC, HashiCorp, or ON Semiconductor?

NEW YORK, Dec. 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSM, ABBV, SHEL, HCP, and ON.

Dec 06, 2023 03:30 pm ET

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remainCerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipelineEmraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditionsTransaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billionAbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CTNORTH CHICAGO, Ill.

Dec 05, 2023 07:45 am ET

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation antibodiesBigHat to receive $30 million upfront payment with potential for further milestone payments and royaltiesNORTH CHICAGO, Ill. and SAN MATEO, Calif., Dec. 5, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and BigHat Biosciences, today announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working closely with AbbVie, BigHat

Dec 04, 2023 04:28 pm ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), Cap

Nov 30, 2023 06:30 am ET

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancerELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancerImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populationsImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignanciesTransaction valued at $31.26 per share in cash, for a total equity value

Nov 29, 2023 07:45 am ET

AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

LUMINOSITY trial demonstrated compelling clinical benefits across key endpointsTeliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpressionData from the study will be presented at a future medical meeting and we will discuss with global health authorities the potential to support an accelerated approvalNORTH CHICAGO, Ill., Nov. 29, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY tr

Nov 27, 2023 06:00 am ET

AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Updates are supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial NORTH CHICAGO, Ill., Nov. 27, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed or refractory (R/R) follicular lymphoma (FL).

Nov 20, 2023 07:45 am ET

Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever

ALLĒ MEMBERS CAN CELEBRATE THE HOLIDAY ALL OF NOVEMBER

Nov 16, 2023 06:00 am ET

Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine

- More patients treated with UBRELVY® 100 mg during the prodrome avoided the development of moderate or severe headache within 24 hours post-dose vs. placebo in those who could identify prodrome symptoms that were reliably followed by headache 1- UBRELVY is the first and only acute treatment for migraine that has demonstrated data in the prodrome phase in a Phase 3, double-blind, placebo-controlled trial- AbbVie is the only company with three prescription treatments designed to meet patient needs across the full spectrum of migraine

Nov 13, 2023 04:05 pm ET

NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year

Nov 08, 2023 07:45 am ET

Natrelle® Unveils New "For Every BODY" Campaign

Refreshed Look Spotlights Most Diverse Breast Implant Portfolio for a Customized Look

Nov 02, 2023 08:31 am ET

Roundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS)

KNGS is the first ever U.S. listed ETF to track the performance of S&P Dividend Monarchs Index, an elite group of blue chip U.S. companies that have grown their dividends for 50+ consecutive years.

Nov 01, 2023 08:45 am ET

BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before

CELEBRATING THE FIFTH ANNUAL BOTOX® COSMETIC DAY, NEW AND LOYAL ALLĒ MEMBERS BENEFIT FROM MORE EXCITING OFFERS

Oct 30, 2023 08:00 am ET

NEXGEL Secures Supply Agreement with AbbVie

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that its subsidiary, CG Converting and Packaging, has...

Oct 27, 2023 07:38 am ET

AbbVie Reports Third-Quarter 2023 Financial Results

Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones ExpenseDelivers Third-Quarter Net Revenues of $13.927 Billion, a Decrease of 6.0 Percent on a Reported Basis and 5.8 Percent on an Operational BasisThird-Quarter Global Net Revenues from the Immunology Portfolio Were $6.783 Billion, a Decrease of 11.3 Percent; Global Humira Net Revenues Were $3.547 Billion; Global Skyrizi Net Revenues Were $

Oct 24, 2023 08:30 am ET

Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines

–All primary and secondary endpoints were met for both Phase 3 studies (M21-500 and M21-508).–Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and short duration of effect within 2-3 weeks.–If approved, BoNT/E will be the first neurotoxin of its kind available to patients.

Oct 19, 2023 08:45 am ET

Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project

Ongoing Support for Breast Cancer Patients Through Initiatives Focused on Education and Elevating Patient Voices

Oct 17, 2023 07:05 am ET

AbbVie's RINVOQ® (upadacitinib) Receives Health Canada Approval as the First and Only Oral Therapy for the Treatment of Adults with Moderately to Severely Active Crohn's Disease

Approval is based on results from three Phase 3 clinical trials demonstrating RINVOQ achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment 1,2,3,4,5Safety results were generally consistent with the known safety profile of RINVOQ, with no new safety risks observed 1-5,6,7,8,9RINVOQ is the first JAK inhibitor indicated in both Crohn's disease and ulcerative colitis, and this approval underscores AbbVie's longstanding commitment to deliver innovative medicines for people living with immune-mediated gastrointestinal diseasesMilesto

Oct 17, 2023 07:00 am ET

AbbVie's EPKINLY™ (epcoritamab injection/epcoritamab for injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients

MONTREAL, Oct. 17, 2023 /CNW/ - AbbVie (NYSE: ABBV), today announced that EPKINLY™ (epcoritamab injection/epcoritamab for injection) has received Health Canada authorization with conditions. It is the first and only subcutaneous (SC) T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b) after two or more lines of system

Oct 15, 2023 11:15 am ET

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs1Risankizumab met both primary endpoints of non-inferiority for clinical remissiona (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic remissionb at week 48 versus ustekinumab1 Risankizumab showed superiority versus ustekinumab for all ranked secondary endpoints, including achievement of clinical remissiona at week 48, achievement of endoscopic responsec at week 48

Oct 12, 2023 05:25 am ET

AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3

At week 24, upadacitinib met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV)1At week 52, the percent reduction from baseline in F-VASI was numerically greater than results at week 24 for all upadacitinib doses1,2The safety profile was consistent with the known safety profile for upadacitinib1,2NORTH CHICAGO, Ill., Oct. 11, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its Phase 2b study evaluating upadacitinib (RINVOQ®) in adults with non-s

Oct 11, 2023 08:30 am ET

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) in treating moderate to severe atopic dermatitis based on results across 140 weeks1 Response rates for EASI 75 and vIGA-AD 0/1 (co-primary endpoints) and for EASI 90 and WP-NRS 0/1 at week 16 were sustained through week 140 among patients treated with RINVOQ1Safety results were consistent with the known safety profile of upadacitinib, with no new safety signals observed1 Data will be presented as an oral presentation at the 32nd European Academ

Oct 10, 2023 08:45 am ET

AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023

– Late-breaking data from a head-to-head study evaluating SKYRIZI® (risankizumab) versus STELARA® (ustekinumab) in moderate to severe Crohn's disease will be presented– Analyses on clinical and endoscopic outcomes from AbbVie's maintenance trials for SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) in moderate to severe Crohn's disease and for RINVOQ in moderate to severe ulcerative colitis– Primary efficacy and safety results from the Phase 3 INSPIRE induction study for risankizumab in ulcerative colitis will be presented– A total of 23 abstracts, including a late-breaker, with 11

Oct 05, 2023 08:05 am ET

AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline

- Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease

Oct 04, 2023 11:07 am ET

Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV), the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication in Nature of the discovery and preclinical data that demonstrate investigational ABBV-CLS-484 is a potential first-in-class, orally bioavailable, PTPN2/N1 phosphatase inhibitor that enhances anti-tumor immunity. The findings, based on research conducted by AbbVie in collaboration with the Broad Institute and Calico, support the development of ABBV-CLS-484 as a promising new strategy for cancer i

Oct 04, 2023 08:00 am ET

AbbVie to Host Third-Quarter 2023 Earnings Conference Call

NORTH CHICAGO, Ill., Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Oct 03, 2023 07:00 am ET

Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field

-- Girls Inc. alumnae in New York, San Antonio and Central Alabama will participate in a virtual panel titled 'Equipping the New Generation of STEM Leaders' with leading women physicians sharing their career journeys including growth moments and challenges --

Sep 29, 2023 07:15 am ET

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasoneResults are being presented at the International Myeloma Society Annual Meeting in Athens, Greece AbbVie will discuss the data with health authorities in the near future to further understand the potential of venetoclax as a biomarker-driven therapy in multiple myeloma NORTH CHICAGO, Ill., Sept. 29, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEX

Sep 25, 2023 07:45 am ET

AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

TEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapyConditional marketing authorization approval from the European Commission is supported by data from the pivotal Phase 1/2 EPCORE™ NHL-1 clinical trialTEPKINLY represents AbbVie's second approved hematological cancer treatment in the European UnionNORTH CHICAGO, Ill., Sept. 25, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has

Sep 19, 2023 08:00 am ET

The Breakthrough Therapy Aiming To Solve The World's Mental Health Crisis

FN Media Group Presents GlobalInvestmentDaily.com Market Commentary

Sep 18, 2023 09:00 am ET

Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence

–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309).–Results support onabotulinumtoxinA as a potential treatment option for moderate to severe platysma prominence.–Data will be included as part of an upcoming U.S. Food and Drug Administration regulatory submission expected near the end of the year. If approved, onabotulinumtoxinA will be the first and only neurotoxin for this indication.

Sep 13, 2023 11:00 am ET

AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"

Online and mobile voting is open to the public now through September 27 to help determine this year's two Thriving Students40 students living with cystic fibrosis (CF) received $3,000 scholarships earlier this year based on their academic excellence, creativity, and community involvementTwo deserving students will be awarded scholarships totaling $25,000 each NORTH CHICAGO, Ill., Sept. 13, 2023 /PRNewswire/ -- AbbVie today announced the start of its two-week public voting period for the 2023 Thriving Undergraduate and Graduate Scholarships. Following this voting period, scholarships totaling

Sep 12, 2023 08:30 am ET

AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs1Risankizumab met both primary endpoints of non-inferiority for clinical remission (Crohn's Disease Activity Index [CDAI]) at week 24 and superiority of endoscopic remission at week 48 versus ustekinumabAll secondary endpoints achieved statistical significance for superiority versus ustekinumabSafety results were consistent with the overall

Sep 07, 2023 07:00 am ET

Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of...

Aug 01, 2023 08:45 am ET

Allergan Aesthetics Announces First Ever JUVÉDERM® Day

The Number One Chosen Dermal Filler Collection Celebrates with Exclusive Offers

Jul 27, 2023 07:38 am ET

AbbVie Reports Second-Quarter 2023 Financial Results

Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second-Quarter Net Revenues of $13.865 Billion, a Decrease of 4.9 Percent on a Reported Basis and 4.2 Percent on an Operational BasisSecond-Quarter Global Net Revenues from the Immunology Portfolio Were $6.813 Billion, a Decrease of 5.5 Percent on a Reported Basis, or 5.0 Percent on an Operational Basis; Global Humira Net

Jul 26, 2023 09:00 am ET

AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

NORTH CHICAGO, Ill. and LA JOLLA, Calif., July 26, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest. This partnership is an expansion of the collaboration AbbVie and Scripps Research formed in 2019 to develop a broad range of potential new and novel therapeutics.

Jul 26, 2023 08:05 am ET

SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study

An open-label, efficacy assessor-blinded study comparing SKYRIZI® (risankizumab) to Otezla® (apremilast) for the treatment of adult patients with moderate plaque psoriasis who were candidates for systemic therapy was published in the British Journal of Dermatology1Significantly more patients in the study achieved co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16 with risankizumab versus apremilast1In apremilast patients not achieving PASI 75 at Week 16, significantly more achieved the primary endpoint of PASI 90 at Week 52 who were re-randomized to risankizumab versus continued with ap

Jul 25, 2023 07:00 am ET

Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Approval is based on results from three Phase 3 studies: two for induction and one for maintenance 1,2,3In clinical trials, patients taking RINVOQ achieved the primary endpoint of clinical remission (per modified Mayo Score [mMS]) at weeks 8 and 52 1,2,3Safety results in ulcerative colitis were generally consistent with the known safety profile of RINVOQ, with no new important safety risks observed 4,5,6,7,8,9Approval underscores AbbVie's longstanding commitment to deliver innovative medicines for people living with immune-mediated gastrointestinal diseasesMilestone marks the sixth Health Ca

Jul 24, 2023 08:05 am ET

AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa

- First registered, randomized Phase 3 trial in hidradenitis suppurativa (HS) evaluating the efficacy and safety of upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe HS1

Jul 21, 2023 04:30 am ET

AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

If approved, epcoritamab (TEPKINLY®) will become the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) DLBCL after two or more lines of systemic therapy The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 Phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with non-Hodgkin's lymphoma (NHL), including DLBCLDLBCL is an aggressive subtype of NHL and accounts for approximately 30 percent of all global casesNORTH CHICAGO, Ill., July

Jul 06, 2023 08:00 am ET

AbbVie to Host Second-Quarter 2023 Earnings Conference Call

NORTH CHICAGO, Ill., July 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2023 financial results on Thursday, July 27, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Jun 28, 2023 06:30 am ET

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its...

Jun 27, 2023 06:50 pm ET

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

- Based on the topline results of epcoritamab from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities to discuss next steps

Jun 26, 2023 08:00 am ET

AbbVie Employees Volunteer During 8th Annual "Week of Possibilities" to Support Communities Globally

– AbbVie's 2023 Week of Possibilities brings more than 14,000 employees together to participate in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact– Week of Possibilities is AbbVie's annual, global volunteering program that unites employees around the world with a single purpose: to give back to local communities through volunteering

Jun 23, 2023 08:04 am ET

AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine

If approved by the European Commission (EC), atogepant will be the first and only once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) for the prophylaxis of migraine in adults who have four or more migraine days per monthThe positive CHMP opinion is based on results from two pivotal Phase 3 studies evaluating atogepant for the prophylaxis of migraine in adults with episodic or chronic migraine NORTH CHICAGO, Ill., June 23, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee fo

Jun 22, 2023 01:13 pm ET

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 22, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share.

Jun 15, 2023 08:45 am ET

Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients

In ulcerative colitis patients with a clinical response to risankizumab induction treatment, a significantly higher proportion of patients treated with risankizumab (180 mg or 360 mg) achieved the primary endpoint of clinical remissiona (per Adapted Mayo Score) at week 52 compared to withdrawal from risankizumab treatment1Key secondary endpoints were met, including endoscopic improvementb, histologic endoscopic mucosal improvementc and steroid-free remissiond at one yearSafety results in this study were consistent with the known safety profile of risankizumab, with no new safety risks observ

Jun 13, 2023 08:45 am ET

BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program

20 GRANT RECIPIENTS ARE SELECTED FROM MORE THAN 6,500 APPLICATIONS TO RECEIVE FUNDING, YEAR-LONG MENTORSHIP, AND COACHING

Jun 09, 2023 03:00 am ET

AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients

Data from two studies continue to show the long-term efficacy and safety of fixed-duration venetoclax combination regimens across different lines of therapy in CLL Six-year median follow-up from the Phase 3 CLL14 study shows continued PFS after treatment with venetoclax plus obinutuzumab compared to treatment with chlorambucil plus obinutuzumab in previously untreated patients with CLL and co-existing conditionsFinal seven-year follow-up results of the Phase 3 MURANO trial demonstrate sustained PFS and overall survival (OS) with venetoclax and rituximab compared to bendamustine and rituximab

Jun 07, 2023 07:01 am ET

AbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under the Non-Insured Health Benefits (NIHB) Program

MONTREAL, June 7, 2023 /CNW/ - AbbVie (NYSE: ABBV), today announced that VRAYLAR is now listed as a Limited Use product on the formulary of the Non-Insured Health Benefits (NIHB)1 program for the treatment of schizophrenia.

Jun 06, 2023 08:00 am ET

AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., June 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. Robert A. Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 10:00 a.m. Central time.

May 31, 2023 02:30 am ET

Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day in patients with moderately to severely active SLE receiving standard lupus therapies1- Upadacitinib maintained greater improvements in SLE disease activity at week 48 as measured by the British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA), SRI-4, Lupus Low Disease

May 25, 2023 08:45 am ET

New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease

NORTH CHICAGO, Ill., May 25, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL, U-EXCEED and U-ENDURE – evaluating upadacitinib (RINVOQ®) in adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent.1-4

May 24, 2023 09:00 am ET

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress

- Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ® (upadacitinib) and HUMIRA® (adalimumab), both in combination with methotrexate (MTX), are reported for adult patients with moderate to severely active rheumatoid arthritis (RA) who had an inadequate response to MTX1

May 19, 2023 12:34 pm ET

EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NORTH CHICAGO, Ill., May 19, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL), after two or more lines of systemic therapies. EPKINLY is approved under the FDA's Accelerated Approval program based on response rate

May 18, 2023 12:25 pm ET

U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults

– The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib) at week 12 and week 52 versus placebo1– Clinical response was achieved by significantly more patients treated with RINVOQ (upadacitinib) versus placebo as early as week 2 in induction studies1– This indication marks the seventh FDA approval for RINVOQ across gastroenterology, rheumatology and dermatology1

May 15, 2023 08:45 am ET

SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval

THE FIRST AND ONLY HYALURONIC ACID INTRADERMAL MICRODROPLET INJECTION, APPROVED FOR IMPROVED SKIN SMOOTHNESS OF THE CHEEKS

May 09, 2023 07:01 am ET

Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1- RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in Canada 1, 2, 3

May 06, 2023 07:30 am ET

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ®) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS®) in treating functional constipation in pediatric patients aged 6 to 17 years

May 02, 2023 08:00 am ET

AbbVie to Present at the Bank of America Securities Healthcare Conference

NORTH CHICAGO, Ill., May 2, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 10:00 a.m. Central time.

Apr 27, 2023 07:32 am ET

AbbVie Reports First-Quarter 2023 Financial Results

Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $12.225 Billion, a Decrease of 9.7 Percent on a Reported Basis and 8.3 Percent on an Operational BasisFirst-Quarter Global Net Revenues from the Immunology Portfolio Were $5.587 Billion, a Decrease of 9.0 Percent on a Reported Basis, or 7.8 Percent on an Operational Basis; Global Humira Net Reve

Apr 21, 2023 12:01 am ET

AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN

The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previously failed two to four classes of conventional oral medications used for preventionThe trial met its primary and secondary endpoints with results showcasing a significant reduction in mean monthly migraine days for those with episodic migraine taking atogepant 60 mg once daily compared to placebo across a 12-week periodData will be presented as part of an oral and poster presentation during the AAN Scientific Platform Session for Emerging Sci

Apr 18, 2023 10:04 am ET

Allergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS

Women surgeons breaking the boundaries of leadership presented in partnership with the American Society of Plastic Surgeons (ASPS), The Aesthetic Society and the American Hernia Society (AHS)

Apr 17, 2023 07:41 pm ET

U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronicExpanded indication provides an additional treatment option for those with chronic migraine whose frequent disabling attacks negatively impact performance of daily activitiesApproval based on a clinical trial that demonstrated statistically significant reduction from baseline in mean monthly migraine days and improvements in function and reduction in activity impairmentAbbVie is the only company with three prescription treatments designed to meet patien

Apr 17, 2023 08:01 am ET

AbbVie Announces Provincial Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia in Québec

MONTREAL, April 17, 2023 /CNW/ - AbbVie (NYSE: ABBV), today announced that VRAYLAR is now listed as an exception medication status on the list of medications of the Régie de l'assurance maladie du Québec (RAMQ)1 for the treatment of schizophrenia.

Apr 17, 2023 02:00 am ET

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease

– Seventh approved indication for RINVOQ in the European Union (EU) and the first and only oral Janus Kinase (JAK) inhibitor approved to treat adult patients with moderately to severely active Crohn's disease

Apr 12, 2023 11:00 am ET

AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year

National scholarship is accepting applications from eligible undergraduate and graduate students now through May 24, 2023 at 11:00 a.m. U.S. Eastern TimeForty exceptional applicants living with cystic fibrosis (CF) will be awarded $3,000 each for academic excellence, creativity and community involvementOne undergraduate and one graduate student will be selected to receive an additional $22,000 each as the 2023 "Thriving Students", determined in part by public votingNORTH CHICAGO, Ill., April 12, 2023 /PRNewswire/ -- AbbVie today announced that the AbbVie Cystic Fibrosis (CF) Scholarship, a p

Apr 04, 2023 08:00 am ET

AbbVie to Host First-Quarter 2023 Earnings Conference Call

NORTH CHICAGO, Ill., April 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Apr 03, 2023 08:00 am ET

CoolSculpting® Elite Announces First Ever CoolMonth

LAUNCHES THE COOLEST PROMOTION WITH A BUY 4, GET 4 DEAL AT PARTICIPATING PROVIDERS TO SUPPORT YOUR BODY CONTOURING JOURNEY

Mar 29, 2023 09:00 am ET

Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023

-- 'Discover Your 360°' immersive experience to feature across Allergan Aesthetics events, supporting customers with all aspects of their Practice, Product and Patient needs --

Mar 23, 2023 09:00 am ET

AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in patients with moderately to severely active SLE1,2No new safety signals were identified with upadacitinib, and a similar safety profile was observed for the combination therapy (ABBV-599) as for treatment with upadacitinib alone2,3,4,5,6,7SLE is a complex autoimmune disorder in which the body's immune sy

Mar 23, 2023 08:30 am ET

Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

A significantly higher proportion of patients with moderately to severely active ulcerative colitis treated with risankizumab achieved the primary endpoint of clinical remissiona (per Adapted Mayo Score) compared to placebo at week 12 in the Phase 3 INSPIRE induction studyAll secondary endpoints, including clinical, endoscopic and histologic outcomes, were metSafety results in this study were consistent with the known safety profile of risankizumab, with no new safety risks observed1Building on AbbVie's growing gastroenterology portfolio, risankizumab is an IL-23 inhibitor being evaluated as

Mar 22, 2023 08:45 am ET

AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application

NORTH CHICAGO, Ill., March 22, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

Mar 18, 2023 10:03 am ET

AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Thera

Treatment with SKYRIZI (risankizumab) demonstrated short- and long-term efficacy of psoriasis signs and symptoms (sPGA 0/1) at week 16 and week 52 in a difficult-to-treat population, with no new safety signals observed in an open-label, single-arm phase 3b studyPatients with moderate to severe psoriasis previously received at least six months of treatment with secukinumab or ixekizumab with a suboptimal response, defined as a static Physician's Global Assessment (sPGA) score of 2 or 3 and body surface area of 3% to <10%, before switching to risankizumabNORTH CHICAGO, Ill., March 18, 2023

Mar 15, 2023 08:03 am ET

AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema

"Under My Skin: Untold Stories of Life with Eczema," uncovers the extraordinary physical and emotional impact of those living with the chronic skin disease, showing viewers the power of having the courage to seek help U.S. audiences can stream the film on The Roku Channel starting April 1NORTH CHICAGO, Ill., March 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the launch of a new documentary film, "Under My Skin: Untold Stories of Life with Eczema," which debuted at South by Southwest® 2023 in Austin, Texas. The film, directed by award-winning Redglass Pictures, features the p

Mar 13, 2023 08:03 am ET

AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

- More than 20 abstracts, including one late-breaking presentation, underscore AbbVie's dedication to advancing care for dermatologic conditions

Mar 08, 2023 07:45 am ET

BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs

NEW PARTNERSHIP PROVIDES TRANSFORMATIVE GRANTS TO EMPOWER CONFIDENCE

Mar 08, 2023 07:00 am ET

AbbVie to Present at the Barclays Global Healthcare Conference

NORTH CHICAGO, Ill., March. 8, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 12:35 p.m. Central time.

Feb 27, 2023 05:00 am ET

AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)

A total of 24 accepted abstracts, including six oral and digital oral presentations, reinforce AbbVie's commitment to research that helps advance standards of care for patients living with inflammatory bowel diseases Data from ADVANCE, MOTIVATE and FORTIFY studies highlighting efficacy outcomes and clinical response in patients receiving SKYRIZI for treatment of moderately to severely active Crohn's disease Oral presentations from sub-analyses of U-EXCEL, U-EXCEED and U-ENDURE address treatment of moderately to severely active Crohn's disease, including efficacy outcomes from the upadacitin

Feb 27, 2023 01:00 am ET

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease

The positive CHMP opinion for upadacitinib is based on results from two induction studies and one maintenance study1-4 Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea and abdominal pain5,6 If approved by the European Commission (EC), this will be the seventh indication for upadacitinib in the European Union (EU), and the first JAK inhibitor for Crohn's disease, adding to AbbVie's gastroenterology portfolioNORTH CHICAGO, Ill., Feb. 27, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the Europ

Feb 16, 2023 11:41 am ET

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Feb. 16, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share.

Feb 09, 2023 06:44 am ET

AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results

Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent; These Results Include an Unfavorable Impact of $0.39 Per Share related to 2022 Acquired IPR&D and Milestones Expense1 Delivers Full-Year Net Revenues of $58.054 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.1 Percent on an Operational BasisFull-Year Global Net Revenues from the Immunology Portfolio Were $28.924 Billion, an Increase of 14.4 Percent on a Reported Basis, or 16.0 Percent on an Operational Basis; Global Humira Net Rev

Jan 25, 2023 08:00 am ET

Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023

IRVINE, Calif., Jan. 25, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports continued innovation and provides cutting-edge products and technologies to help practitioners and patients' aesthetics needs today and for the future.

Jan 18, 2023 07:00 am ET

JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE

With JUVÉDERM® VOLUX™ XC, You Can Receive Non-Surgical Jawline Augmentation in Your Aesthetic Provider's Office

Jan 17, 2023 07:00 am ET

SkinMedica® Launches Even & Correct

The Results Are Clear - A Scientifically Proven Path to Targeting the Appearance of Hyperpigmentation and Improving Skin Tone and Texture

Jan 16, 2023 09:00 am ET

Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the termination of the Rodan + Fields (R+F) agreement for supply and use of TFC-1067 in commercial formulations. Allergan Aesthetics, an AbbVie company (NYSE: ABBV),...

Jan 10, 2023 07:00 am ET

AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

- Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology- Anima will receive an upfront payment of $42 million with potential for further milestones and royalties

Jan 09, 2023 06:01 am ET

QULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults

QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic migraine. AbbVie is the only pharmaceutical company to offer three treatments across the full spectrum of migraine to help patients living with this debilitating disease. MONTRÉAL, Jan. 9, 2023 /CNW Telbec/ - AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of episodic migraine (< 15 migraine days per month) in adults.1 QULIPTA, the first and only oral calcitonin ge

Jan 06, 2023 08:00 am ET

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.

Jan 06, 2023 07:00 am ET

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

- Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine- Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties

Jan 05, 2023 07:00 am ET

AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call

NORTH CHICAGO, Ill., Jan. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Jan 03, 2023 07:00 am ET

AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Jan. 3, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Richard A. Gonzalez, chairman and chief executive officer, will present at 5:00 p.m. CT.

Dec 16, 2022 05:39 pm ET

U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder

- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant therapy (ADT), showing improvement in symptoms when compared to placebo + ADT

Dec 16, 2022 06:30 am ET

AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age

If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1Submission is based on positive Phase 3 study data demonstrating linaclotide (72mcg) resulted in increases in frequency of spontaneous bowel movements (SBM) and improved stool consistency in children and adolescents aged 6 to 17 yearsNORTH CHICAGO, Ill., Dec. 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food and Drug Administration (

Dec 12, 2022 11:59 am ET

AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year

AbbVie Ranked #1 in Biotech Sector on the 2022 S&P Corporate Sustainability Assessment NORTH CHICAGO, Ill., Dec. 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that for the tenth consecutive year, it has been named to the Dow Jones Sustainability World Index (DJSI World) and Dow Jones Sustainability North America Index (DJSI North America). Additionally, AbbVie achieved the highest score in the biotech sector on the 2022 S&P Global Corporate Sustainability Assessment (CSA). Since AbbVie's founding in 2013, the company has been listed on the DJSI World and DJSI North Ame

Dec 11, 2022 04:30 pm ET

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) follicular lymphoma, previously untreated follicular lymphoma, R/R diffuse large B-cell lymphoma and Richter's syndrome NORTH CHICAGO, Ill., Dec. 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in combination for the treatment of patients with relapsed/refractory (R/R) follicular lymphoma (FL), previ

Dec 10, 2022 02:00 pm ET

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients

Exploratory analysis from Cohort 3 of the Phase 2 REFINE study presented in an oral session at ASH NORTH CHICAGO, Ill., Dec. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis (MF). The exploratory analysis suggests the combination of navitoclax and ruxolitinib led to reductions in bone marrow fibrosis (BMF) and variant allele frequency (VAF) for common genetic mutations found in individuals with myelofibrosis that may i

Dec 10, 2022 10:15 am ET

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science

Updated data presented at ASH include CAPTIVATE and GLOW studies and real-world evidence abstracts NORTH CHICAGO, Ill., Dec. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia (CLL). Presentations featured during the 64th American Society of Hematology (ASH) Annual Meeting and Exposition will include two clinical trials investigating once daily, fixed-duration treatment with IMBRUVICA® (ibrutinib) plus VENCLEXTA®/VENCLYXTO® (venetoclax) (I+V) in adults with CLL and several analyses from rea

Dec 06, 2022 07:00 am ET

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

Collaboration leverages HotSpot's Smart Allostery™ drug discovery platform for the development of the first and only small molecule IRF5 (interferon regulatory factor 5) inhibitor for the potential treatment of autoimmune diseasesHotSpot to receive an upfront cash payment of $40 million with potential for further milestones and royaltiesNORTH CHICAGO, Ill. and BOSTON, Dec. 6, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune

Dec 06, 2022 01:00 am ET

AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress

-- Fifteen abstracts underscore AbbVie's commitment to people living with migraine-- AbbVie to present late-breaking data from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study on neck pain with headache in people with and without migraine -- Results from the PROGRESS Phase 3 trial on atogepant for the preventive treatment of chronic migraine in Europe will also be presented

Dec 01, 2022 08:25 am ET

Optimism Building for Advancing Pancreatic Cancer Treatment Therapies

PALM BEACH, Fla. , Dec. 1, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts for over 3% of all types of cancers in US. A lethal type of cancer, pancreatic cancer starts in the pancreas of the human body when abnormal cells in the pancreas grow and divide out of control and form a tumor. The presence of tumors prevents the normal functioning of the pancreas. The occurrence and mortality rate of pancreatic cancer is more in men than in women. Pancreatic cancer starts when the cells start growing abnormally and results in symptoms such as abdominal pain,

Dec 01, 2022 06:01 am ET

AbbVie Announces Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

MONTREAL, Dec. 1, 2022 /CNW/ - AbbVie (NYSE: ABBV), today announced that RINVOQ is now listed as a special authorization medication or exception medication status on the formularies of Alberta1, New Brunswick2, Ontario3, Quebec4 and Saskatchewan5 for the treatment of adults with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). In addition, RINVOQ is now listed as a Limited Use product on the formulary of the Non-Insured Health Benefits program (NIHB)6 for the treatment of RA and PsA.

Nov 24, 2022 06:01 am ET

The Impact of Inaction - New Publication Reveals Not All of Canada is on Track to Meet Global Hepatitis C Elimination Goal

Timing of elimination of the hepatitis C virus (HCV) in Canada's provinces indicates 70% of provinces could reach the World Health Organization's (WHO) HCV elimination target of 2030, however three of Canada's provinces — two of them the most populous in the country — are off track to achieve this hepatitis C elimination goal.1Timely elimination would save 170 lives and $122.6 million in direct medical costs in these three provinces by 2030.1The Progress Report developed by Action Hepatitis Canada outlines key metrics on which to evaluate HCV elimination progress in Canada, specific to each

Nov 23, 2022 07:00 am ET

AbbVie to Present at the Evercore ISI HealthCONx Conference

NORTH CHICAGO, Ill., Nov. 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Tom Hudson senior vice president, R&D and chief scientific officer, will present at 9:55 a.m. Central time.

Nov 23, 2022 01:00 am ET

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease

- Third approved indication for SKYRIZI® (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU) - A significantly higher proportion of patients on SKYRIZI achieved clinical remission, endoscopic response, mucosal healing and endoscopic remission at week 12 in induction studies compared to placebo1,2,3- A significantly higher proportion of patients achieved clinical remission and endoscopic response at week 52 with SKYRIZI maintenance1,2,3- Crohn's disease is a chronic, systemic inflammatory disease tha

Nov 22, 2022 02:45 pm ET

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

- Nearly 65 abstracts, including 15 oral presentations on 7 investigational and approved medicines across 8 cancer types, to be presented at the American Society of Hemaotology (ASH) annual congress

Nov 22, 2022 08:00 am ET

AbbVie to Present at the Piper Sandler Healthcare Conference

NORTH CHICAGO, Ill., Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Tom Hudson senior vice president, R&D and chief scientific officer, will present at 8:30 a.m. Central time.

Nov 21, 2022 07:00 am ET

U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

The application is supported by data from EPCORE™ NHL-1 Phase 1/2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma, including large B-cell lymphomaIf approved for relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy, epcoritamab could become the first subcutaneous bispecific antibody available for the treatment of large B-cell lymphomaNORTH CHICAGO, Ill., Nov. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S.

Nov 17, 2022 07:45 am ET

Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet

A RECORD-BREAKING NUMBER OF CONSUMERS PARTICIPATED, WITH BOGO GIFT CARDS SELLING OUT IN JUST A FEW HOURS11

Nov 16, 2022 08:00 am ET

Canadian Migraine Sufferers Have New Treatment Option - Health Canada Approves UBRELVY® (ubrogepant tablet)

- UBRELVY® is the first and only oral CGRP receptor antagonist (gepant) approved by Health Canada for the acute treatment of migraine

Nov 09, 2022 07:00 am ET

AbbVie to Present at the Wolfe Research Healthcare Conference

NORTH CHICAGO, Ill., Nov. 9, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 4th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Neil Gallagher, vice president development and chief medical officer will present virtually at 10:30 a.m. Central time.

Nov 08, 2022 01:00 pm ET

AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022

Thirty-six abstracts underscore AbbVie's commitment to advancing research to help more people living with rheumatic diseasesAdditional analysis of long-term safety data for RINVOQ® (upadacitinib) and SKYRIZI® (risankizumab)NORTH CHICAGO, Ill., Nov. 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI® (risankizumab) for psoriasis and psoriatic arthritis at the American College of Rheumatology's annual meeti

Nov 07, 2022 11:31 am ET

AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Pat

Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patientsData showed relative risk reduction in specific study populations and overall lower rates of rehospitalization within 30 days compared to placeboAdverse Events (AEs) were numerically similar across treatment groups Results were presented today as part of a late-breaking science session at the 2022 American Heart Association Scientific SessionsNORTH CHICAGO, Ill., Nov. 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new

Nov 03, 2022 08:00 am ET

Allergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer Awareness

PINK RIBBON STRONG 365 IS DEDICATED TO PROVIDING EDUCATIONAL INITIATIVES AND SHARING REAL STORIES TO SUPPORT PATIENTS, SURVIVORS, AND PREVIVORS

Nov 02, 2022 08:00 am ET

Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

THE ICONIC BRAND ENCOURAGES PEOPLE TO TAKE A 'MOMENT FOR YOU' WITH TWO EXCLUSIVE OFFERS FOR FAMILY AND FRIENDS, POWERED BY ALLĒ

Oct 28, 2022 08:45 am ET

AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LB

European Medicines Agency (EMA) validates AbbVie's Marketing Authorization Application; Genmab submits Biologics License Application to U.S. Food and Drug Administration (FDA)The submissions are supported by the EPCORE™ NHL-1 open-label, multi-center Phase 2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL)NORTH CHICAGO, Ill., Oct. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketi

Oct 28, 2022 07:44 am ET

AbbVie Reports Third-Quarter 2022 Financial Results

Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66, an Increase of 29.3 Percent; These Results Include an Unfavorable Impact of $0.02 Per Share related to Acquired IPR&D and Milestones Expense 1Delivers Third-Quarter Net Revenues of $14.812 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.4 Percent OperationallyThird-Quarter Global Net Revenues from the Immunology Portfolio Were $7.651 Billion, an Increase of 14.6 Percent on a Reported Basis, or 16.4 Percent on an Operational Basis; U.S. Humira Net Revenues

Oct 24, 2022 07:00 am ET

AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting

Data illustrates AbbVie's commitment to providing research and innovative solutions that support patients with high disease burden and unmet needOral presentations address treatment of moderate to severe Crohn's disease, including efficacy and safety outcomes from the SKYRIZI® (risankizumab-rzaa) pivotal clinical program as well as late-breaking Phase 3 investigational data from the upadacitinib 52-week maintenance trialPoster presentations include an analysis of the impact of CREON® (pancrelipase) on patient-reported daily symptoms in exocrine pancreatic insufficiency due to chronic pancrea

Oct 21, 2022 04:42 pm ET

RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval

RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is the first and only JAK inhibitor approved for both active ankylosing spondylitis (AS) and nr-axSpA1-3In a clinical study, RINVOQ delivered rapid and meaningful disease control based on patients achieving ASAS40 vs. placebo, as well as significant improvement in signs and symptoms of nr-axSpA at week 141,2NORTH CHICAGO, Ill., Oct. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announces that the U.S. Food and Drug Administration (FDA) has appr

Oct 20, 2022 09:00 am ET

AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline

-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases

Oct 20, 2022 08:45 am ET

AbbVie's SKYRIZI® (risankizumab) Receives Health Canada Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

Third approved indication for SKYRIZI (rizankizumab) is supported by safety and efficacy data from two induction and one maintenance Phase 3 clinical trials: ADVANCE, MOTIVATE and FORTIFY 1,2,3,As early as Week 4 in the induction studies, clinical response and clinical remission were achieved by significantly more people treated with SKYRIZI versus placebo 1,2,3Approval represents AbbVie's longstanding dedication to delivering innovative medicines for people living with immune-mediated gastroenterological diseasesMONTREAL, Oct. 20, 2022 /CNW/ - AbbVie (NYSE: ABBV) today announced Health Cana

Oct 17, 2022 09:00 am ET

AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire

Perry Siatis Named as Executive Vice President, General Counsel and Secretary

Oct 13, 2022 07:01 am ET

For World Sight Day, new app available for Canadians living with glaucoma, the Silent Thief of Sight

MONTREAL, Oct. 13, 2022 /CNW/ - AbbVie (NYSE: ABBV) and Fighting Blindness Canada have launched the Glaucoma in Perspective (GiP) app to help Canadians understand the impact of glaucoma and manage disease progression. The launch of GiP coincides with World Sight Day, as the vision loss community comes together to raise awareness and understanding of eye diseases like glaucoma.

Oct 07, 2022 02:05 pm ET

Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio at the 2022 American Society for Dermatologic Surgery Meeting

–Data results shared across facial injectables, body contouring and skincare portfolio highlights Allergan Aesthetics' continued commitment to advancing aesthetic medicine–Analyses of 15 years of post-marketing surveillance data demonstrate the global reported rate of delayed-onset nodules associated with dermal fillers on the Vycross technology platform is low (<0.016%).–Results from 3 clinical studies showcasing a customizable platform with patent-pending LTN Complex, to address the appearance of facial hyperpigmentation in a wide range of demographic populations–Dr. DiAnne Davis to dis

Oct 04, 2022 08:00 am ET

AbbVie to Host Third-Quarter 2022 Earnings Conference Call

NORTH CHICAGO, Ill., Oct. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Sep 29, 2022 07:00 am ET

AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022

Final analyses from the U-ACHIEVE Phase 3 maintenance study of RINVOQ® (upadacitinib) in moderately to severely active ulcerative colitisData highlighting symptomatic and endoscopic outcomes, delayed subcutaneous responders and predictors of response in patients receiving risankizumab (SKYRIZI®) for use in moderate to severe Crohn's disease*Data from the Phase 3 study U-EXCEL evaluating the efficacy and safety of upadacitinib (RINVOQ®) as induction therapy for use in adults with moderately to severely active Crohn's disease*A total of 17 abstracts, including seven oral presentations, reinfor

Sep 27, 2022 07:01 am ET

XEN® 63 Gel Implant available now for patients with primary open angle glaucoma where previous medical treatments have failed

The XEN 63 Gel Implant is intended to reduce intraocular pressure (IOP) in patients with primary open angle glaucoma1 XEN 63 is a minimally invasive, micro-incisional glaucoma surgery designed to lower IOP2 XEN 63 Gel Implant provides innovative treatment option for Canadians impacted by glaucoma MONTREAL, Sept. 27, 2022 /CNW/ - AbbVie (NYSE: ABBV) announced today the availability of the XEN® 63 Gel Implant, a surgical implant designed to lower high eye pressure in open angle glaucoma sufferers, where previous medical treatment options have failed.1 The XEN 63 Gel Implant is an additional op

Sep 22, 2022 08:00 am ET

The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery

--Initiative Creates Groundbreaking New, Royalty Free Inclusive Image Gallery In Strategic Partnership with Shutterstock Studios--

Sep 19, 2022 02:00 am ET

AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease

- CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2- Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain and can require urgent medical care3,4- If approved, risankizumab will be the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU)- The European Commission decision is expected in the fourth quarter of 2022. This anticipated approval would mark the third indication for risanki

Sep 15, 2022 02:00 am ET

AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress

--Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in people with advanced Parkinson's disease --Data will also be presented on real-world efficacy of BOTOX® (onabotulinumtoxinA) for the treatment of spasticity and BOTOX® for the treatment of cervical dystonia--Research highlights AbbVie's continued commitment to advancing the management of movement disorders

Sep 14, 2022 11:15 am ET

AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship "Thriving Student Awards"

Online and mobile voting is open to the public now through September 28 to help determine this year's two Thriving ScholarsForty students living with cystic fibrosis (CF) are in the running for the two $25,000 awards based on their academic excellence, creativity, and community involvement/extracurricular activitiesThis year's scholarship program marks 30 years of AbbVie's commitment to students with CF pursuing higher educationNORTH CHICAGO, Ill., Sept. 14, 2022 /PRNewswire/ -- AbbVie today announced the start of its two-week public voting period for the 2022 Thriving Undergraduate and Grad

Sep 13, 2022 08:45 am ET

Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories

NEARLY 20,000 PEOPLE RESPONDED TO AN OPEN CASTING CALL FOR A CHANCE TO BE FEATURED IN THE UPCOMING CAMPAIGN FOR THE NUMBER ONE SELLING PRODUCT OF ITS KIND

Sep 10, 2022 03:20 am ET

New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100

- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis1

Sep 09, 2022 10:26 am ET

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Sept. 9, 2022 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.

Sep 08, 2022 04:30 am ET

New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients

MEASURE-AD was a real-world study of moderate to severe atopic dermatitis patients across 28 countries designed to assess the multidimensional burdens that diagnosed patients face1-3Additional findings show that lower clinical burden and work impairment had a positive association with quality of life and lower disease severity scores1Atopic dermatitis, also known as eczema, impacts up to an estimated 10 percent of adults and 25 percent of children globally and causes significant physical, psychological and economic impact4-7NORTH CHICAGO, Ill., Sept. 8, 2022 /PRNewswire/ -- An analysis from

Sep 08, 2022 04:00 am ET

AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022

--Results from the PROGRESS Phase 3 trial on atogepant for the preventive treatment of chronic migraine will be showcased as an oral presentation

Sep 07, 2022 08:45 am ET

Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM®

JUVÉDERM® Collection of Fillers Continues Position as the World's Number One Chosen Dermal Filler Collection

Sep 07, 2022 08:00 am ET

AbbVie to Present at the Morgan Stanley Healthcare Conference

NORTH CHICAGO, Ill., Sept. 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Rob Michael, vice chairman and president, Jeff Stewart, executive vice president, commercial operations, and Neil Gallagher, vice president development and chief medical officer will present at 9:35 a.m. Central time.

Aug 31, 2022 09:00 am ET

SkinMedica® Launches Firm & Tone Lotion for Body

Powerful, Effective, Targeted Topical Treatment Formulated to Prevent and Address Visible Signs of Body Skin Aging

Aug 30, 2022 08:00 am ET

Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report

-- Report is aimed at helping practitioners and the industry prepare for the future by supporting the evolving needs of patients --

Aug 29, 2022 08:00 am ET

AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress

Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI® (risankizumab) in moderate to severe psoriasis and active psoriatic arthritis Presentations include data from the largest-of-its-kind study that demonstrates the real-world burden of atopic dermatitisBreadth of data underscores AbbVie's commitment to advancing research in dermatology for people living with immune-mediated skin diseases such as psoriasis, psoriatic arthritis, atopic dermatitis and vitiligoNORTH CHICAGO, Ill., Aug. 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today ann

Aug 24, 2022 07:21 pm ET

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)

The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after failure of one or more lines of systemic therapyThis is the first approved treatment option for children with cGVHD under 12 years of age and the only Bruton's tyrosine kinase inhibitor (BTKi) treatment for a pediatric patient populationcGVHD is a rare condition that can occur in patients after receiving peripheral blood or bone marrow stem cell transplantation often related to blood cancer treatmentIMBRUVICA was the first treatment approved in the U

Aug 17, 2022 08:45 am ET

Experience the JUVÉDERM® Difference with Allergan Aesthetics

Allē Double Point Promotion Encourages Consumers to See the JUVÉDERM® Difference

Aug 12, 2022 10:50 pm ET

ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into AbbVie Inc. (NYSE: ABBV).

Aug 03, 2022 08:45 am ET

FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition

JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION

Aug 01, 2022 07:05 pm ET

Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases

Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and...

Jul 29, 2022 10:50 pm ET

ABBVIE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV

NEW ORLEANS, July 29, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into AbbVie Inc. (NYSE: ABBV).

Jul 29, 2022 07:41 am ET

AbbVie Reports Second-Quarter 2022 Financial Results

Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent; Adjusted Diluted EPS of $3.37, an Increase of 11.2 Percent; These Results Include an Unfavorable Impact of $0.14 Per Share related to Acquired IPR&D and Milestones Expense 1 Delivers Second-Quarter Net Revenues of $14.583 Billion, an Increase of 4.5 Percent on a Reported Basis and 6.1 Percent Operationally Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.207 Billion, an Increase of 17.8 Percent on a Reported Basis, or 19.2 Percent on an Operational Basis; U.S. Humira Net Reve

Jul 29, 2022 02:00 am ET

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® (upadacitinib 15 mg, once daily) is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the European Union (EU)1Approval is supported by data from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered meaningful disease control with nearly half of nr-axSpA patients achieving ASAS40 at week 14 (45 percent versus 23 percent; p<0.0001) compared to placebo2NORTH CHICAGO, Ill., July 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today ann

Jul 27, 2022 08:45 am ET

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease

Submissions are supported by three Phase 3 clinical trials demonstrating upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment1-4Safety results were generally consistent with the known safety profile of upadacitinib, with no new safety risks observed1-8Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea and abdominal pain9,10NORTH CHICAGO, Ill., July 27, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submi

Jul 26, 2022 02:00 am ET

European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis

RINVOQ (upadacitinib) is now approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent1The approval is based on the results of three Phase 3 studies: two for induction and one for maintenance1,2In these clinical trials, RINVOQ achieved the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8 in induction studies and week 52 in the maintenance study, and all secondary endpoints, includi

Jul 25, 2022 08:00 am ET

AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference

– Data analyses of onabotulinumtoxinA (BOTOX®) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and long-term use

You are here

AbbVie Inc (N:ABBV)

Business Focus: Pharmaceuticals